UroGen Pharma Ltd. (URGN)
43.62
-1.88
(-4.13%)
USD |
NASDAQ |
Aug 28, 16:00
43.61
-0.01
(-0.02%)
After-Hours: 20:00
UroGen Pharma Enterprise Value : 2.219B for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | 2.219B |
| August 27, 2026 | 2.310B |
| August 26, 2026 | 2.332B |
| August 25, 2026 | 2.352B |
| August 24, 2026 | 2.343B |
| August 21, 2026 | 2.377B |
| August 20, 2026 | 2.374B |
| August 19, 2026 | 2.544B |
| August 18, 2026 | 2.478B |
| August 17, 2026 | 2.488B |
| August 14, 2026 | 2.443B |
| August 13, 2026 | 2.438B |
| August 12, 2026 | 2.481B |
| August 11, 2026 | 2.389B |
| August 10, 2026 | 2.350B |
| August 07, 2026 | 2.382B |
| August 06, 2026 | 2.315B |
| August 05, 2026 | 2.356B |
| August 04, 2026 | 2.038B |
| August 03, 2026 | 1.973B |
| July 31, 2026 | 1.956B |
| July 30, 2026 | 2.095B |
| July 29, 2026 | 2.064B |
| July 28, 2026 | 2.085B |
| July 27, 2026 | 2.113B |
| Date | Value |
|---|---|
| July 24, 2026 | 2.089B |
| July 23, 2026 | 2.164B |
| July 22, 2026 | 2.142B |
| July 21, 2026 | 2.226B |
| July 20, 2026 | 2.096B |
| July 17, 2026 | 2.053B |
| July 16, 2026 | 2.042B |
| July 15, 2026 | 2.032B |
| July 14, 2026 | 2.002B |
| July 13, 2026 | 2.018B |
| July 10, 2026 | 1.971B |
| July 09, 2026 | 2.053B |
| July 08, 2026 | 1.945B |
| July 07, 2026 | 1.932B |
| July 06, 2026 | 1.915B |
| July 02, 2026 | 1.945B |
| July 01, 2026 | 1.941B |
| June 30, 2026 | 1.885B |
| June 29, 2026 | 1.812B |
| June 26, 2026 | 1.738B |
| June 25, 2026 | 1.730B |
| June 24, 2026 | 1.781B |
| June 23, 2026 | 1.768B |
| June 22, 2026 | 1.760B |
| June 18, 2026 | 1.691B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Insmed, Inc. | 25.46B |
| Xencor, Inc. | 1.651B |
| MeiraGTx Holdings Plc | 1.271B |
| IDEAYA Biosciences, Inc. | 3.066B |
| ACADIA Pharmaceuticals, Inc. | 4.128B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.35M |
| Revenue (Quarterly) | 72.46M |
| Total Expenses (Quarterly) | 86.81M |
| EPS Diluted (Quarterly) | -0.2848 |
| Gross Profit Margin (Quarterly) | 90.93% |
| Profit Margin (Quarterly) | -19.81% |
| Earnings Yield | -4.57% |
| Normalized Earnings Yield | -4.571 |